Tim Duffy

About Tim Duffy

Tim Duffy has more than 25 years of executive leadership, business development, marketing and commercial experience in the life science and healthcare industry. Tim is the Vice President of Business Development for Omeros Corporation a publicly held biopharmaceutical company focused on PharmacoSurgery, neurology, psychiatry, surgical bleeding, orphan diseases and novel drug targets. Most recently he was the founder and Managing Director of Pacific Crest Ventures, a life science consultancy. Prior to Pacific Crest Ventures, Tim was the Chief Business Officer of MDRNA Inc.(formerly Nastech Pharmaceutical Co.), a publicly held biopharmaceutical company focused on the non-invasive delivery of peptide therapeutics and the development of RNA-based therapeutics. Tim was instrumental in developing and executing Nastech\'s partnering strategies and managing business development, marketing, IP, legal and manufacturing operations. This resulted in the execution of a series of licensing transactions worth more than $1 billion, that tripled the company\'s market capitalization. Tim has more than fifteen years of successful transactional experience that has included licensing, acquisitions, joint ventures, mergers, spin-outs and financing activities. These transactions have been in biotech, pharmaceuticals and diagnostics. For more than 20 years he has focused on pharmaceutical, biotech and diagnostic product sales, marketing, and strategy. From 1997 through 2004 Tim was a Vice President at Prometheus Laboratories responsible for licensing and acquisition of the technology and products that built this privately held company to a successful and cash flow positive company in just four years. Prior to Prometheus Tim spent 13 years at Procter & Gamble Pharmaceuticals in a broad array of sales, marketing and strategic planning roles.Specialties: Executive management, strategy development, licensing, mergers and acquisitions, sales, marketing & commercial operations

Experience

1. Vice President, Business Development

   Omeros Corporation

   Mar 2010 — Present

   I am responsible for the licensing and commercialization of Omeros\' products and technologies. Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Our most clinically advanced product candidates are derived from our proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Our PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery. We currently have five ongoing clinical development programs, including four from our PharmacoSurgery platform and one from our Addiction program, the most advanced of which are in Phase 3 clinical trials. In addition, we have leveraged our expertise in inflammation and the central nervous system to build a deep and diverse pipeline of preclinical programs targeting large markets as well as a platform capable of unlocking new drug targets.

Education

• Loras College

  BS, Biology

  1979 — 1983

Skills

• Business Development
• Neurology
• Mergers
• Venture Capital
• Technology Transfer
• Start-Ups
• Pharmaceutical Sales
• Drug Delivery
• Validation
• Biochemistry
• Clinical Trials
• Drug Development
• Gcp
• Biopharmaceuticals
• Pharmaceutical Industry
• Fda
• Strategic Partnerships
• Glp
• Sales
• Leadership
• Clinical Development
• Life Sciences
• Pharmaceutics
• Drug Discovery
• Oncology
• Strategy
• Medical Devices
• Clinical Research
• Mergers & Acquisitions
• Executive Management
• Biotechnology
• Immunology
• Assay Development
• Licensing
• CRO
• Commercialization
• Molecular Biology
• Strategic Planning
• Regulatory Affairs
• Lifesciences